{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:55:00Z","timestamp":1793436900591,"version":"4.5.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gout flare prophylaxis and therapy use in people with underlying chronic kidney disease (CKD) is challenging, given limited treatment options and risk of worsening renal function with inappropriate treatment dosing. This literature review aimed to describe the current literature on the efficacy and safety of gout flare prophylaxis and therapy use in people with CKD stages 3\u20135. A literature search via PubMed, the Cochrane Library, and EMBASE was performed from 1 January 1959 to 31 January 2018. Inclusion criteria were studies with people with gout and renal impairment (i.e. estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl) &lt;\u200960\u2009ml\/min\/1.73\u2009m<jats:sup>2<\/jats:sup>), and with exposure to colchicine, interleukin-1 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), and glucocorticoids. All study designs were included. A total of 33 studies with efficacy and\/or safety analysis stratified by renal function were reviewed\u2014colchicine (<jats:italic>n<\/jats:italic>\u2009=\u200920), anakinra (<jats:italic>n<\/jats:italic>\u2009=\u20097), canakinumab (<jats:italic>n<\/jats:italic>\u2009=\u20091), NSAIDs (<jats:italic>n<\/jats:italic>\u2009=\u20093), and glucocorticoids (<jats:italic>n<\/jats:italic>\u2009=\u20092). A total of 58 studies reported these primary outcomes without renal function stratification\u2014colchicine (<jats:italic>n<\/jats:italic>\u2009=\u200929), anakinra (<jats:italic>n<\/jats:italic>\u2009=\u200910), canakinumab (<jats:italic>n<\/jats:italic>\u2009=\u20096), rilonacept (<jats:italic>n<\/jats:italic>\u2009=\u20092), NSAIDs (<jats:italic>n<\/jats:italic>\u2009=\u20091), and glucocorticoids (<jats:italic>n<\/jats:italic>\u2009=\u200910). Most clinical trials excluded study participants with severe CKD (i.e. eGFR or CrCl of &lt;\u200930\u2009mL\/min\/1.73\u2009m<jats:sup>2<\/jats:sup>). Information on the efficacy and safety outcomes of gout flare prophylaxis and therapy use stratified by renal function is lacking. Clinical trial results cannot be extrapolated for those with advanced CKD. Where possible, current and future gout flare studies should include patients with CKD and with study outcomes reported based on renal function and using standardised gout flare definition.<\/jats:p>","DOI":"10.1186\/s13075-021-02416-y","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T07:06:30Z","timestamp":1619593590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review"],"prefix":"10.1186","volume":"23","author":[{"given":"Huai Leng","family":"Pisaniello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamish","family":"Farquhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz","family":"Vargas-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine L.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0138-2912","authenticated-orcid":false,"given":"Lisa K.","family":"Stamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo L.","family":"Gaffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"issue":"11","key":"2416_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","volume":"11","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649\u201362. https:\/\/doi.org\/10.1038\/nrrheum.2015.91.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"2416_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/rheumatology\/kes211","volume":"52","author":"LK Stamp","year":"2013","unstructured":"Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. Rheumatology (Oxford). 2013;52(1):34\u201344. https:\/\/doi.org\/10.1093\/rheumatology\/kes211.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"2416_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","volume":"125","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012;125(7):679\u201387 e1. https:\/\/doi.org\/10.1016\/j.amjmed.2011.09.033.","journal-title":"Am J Med"},{"issue":"11","key":"2416_CR4","doi-asserted-by":"publisher","first-page":"e50046","DOI":"10.1371\/journal.pone.0050046","volume":"7","author":"E Krishnan","year":"2012","unstructured":"Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009-10. PLoS One. 2012;7(11):e50046. https:\/\/doi.org\/10.1371\/journal.pone.0050046.","journal-title":"PLoS One"},{"issue":"1","key":"2416_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12916-017-0922-5","volume":"15","author":"R Terkeltaub","year":"2017","unstructured":"Terkeltaub R. What makes gouty inflammation so variable? BMC Med. 2017;15(1):158. https:\/\/doi.org\/10.1186\/s12916-017-0922-5.","journal-title":"BMC Med"},{"key":"2416_CR6","doi-asserted-by":"publisher","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. American College of Rheumatology Guideline for the management of gout. Arthritis Care Res. 2020;2020. https:\/\/doi.org\/10.1002\/acr.24180.","DOI":"10.1002\/acr.24180"},{"issue":"3","key":"2416_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1053\/j.ajkd.2017.01.055","volume":"70","author":"AB Vargas-Santos","year":"2017","unstructured":"Vargas-Santos AB, Neogi T. Management of gout and hyperuricemia in CKD. Am J Kidney Dis. 2017;70(3):422\u201339. https:\/\/doi.org\/10.1053\/j.ajkd.2017.01.055.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2416_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13075-020-2120-7","volume":"22","author":"S Stewart","year":"2020","unstructured":"Stewart S, Yang KCK, Atkins K, Dalbeth N, Robinson PC. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2020;22(1):28. https:\/\/doi.org\/10.1186\/s13075-020-2120-7.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"2416_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1445-5994.1987.tb01232.x","volume":"17","author":"MJ Ahern","year":"1987","unstructured":"Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust NZ J Med. 1987;17(3):301\u20134. https:\/\/doi.org\/10.1111\/j.1445-5994.1987.tb01232.x.","journal-title":"Aust NZ J Med"},{"issue":"12","key":"2416_CR10","first-page":"2429","volume":"31","author":"GC Borstad","year":"2004","unstructured":"Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31(12):2429\u201332.","journal-title":"J Rheumatol"},{"issue":"14","key":"2416_CR11","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","volume":"32","author":"RL Wortmann","year":"2010","unstructured":"Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010;32(14):2386\u201397. https:\/\/doi.org\/10.1016\/j.clinthera.2011.01.008.","journal-title":"Clin Ther"},{"issue":"6","key":"2416_CR12","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.jbspin.2015.10.006","volume":"83","author":"T Pascart","year":"2016","unstructured":"Pascart T, Lancrenon S, Lanz S, Delva C, Guggenbuhl P, Lambert C, et al. GOSPEL 2 - colchicine for the treatment of gout flares in France - a GOSPEL survey subgroup analysis. Doses used in common practices regardless of renal impairment and age. Joint Bone Spine. 2016;83(6):687\u201393. https:\/\/doi.org\/10.1016\/j.jbspin.2015.10.006.","journal-title":"Joint Bone Spine"},{"issue":"6","key":"2416_CR13","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1097\/MJT.0b013e31825a364a","volume":"21","author":"Y Solak","year":"2014","unstructured":"Solak Y, Atalay H, Biyik Z, Alibasic H, Gaipov A, Guney F, et al. Colchicine toxicity in end-stage renal disease patients: a case-control study. Am J Ther. 2014;21(6):e189\u201395. https:\/\/doi.org\/10.1097\/MJT.0b013e31825a364a.","journal-title":"Am J Ther"},{"issue":"3","key":"2416_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1086\/431592","volume":"41","author":"IF Hung","year":"2005","unstructured":"Hung IF, Wu AK, Cheng VC, Tang BS, To KW, Yeung CK, et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis. 2005;41(3):291\u2013300. https:\/\/doi.org\/10.1086\/431592.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2416_CR15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.amjmed.2016.12.006","volume":"130","author":"OC Kwon","year":"2017","unstructured":"Kwon OC, Hong S, Ghang B, Kim YG, Lee CK, Yoo B. Risk of colchicine-associated myopathy in gout: influence of concomitant use of statin. Am J Med. 2017;130(5):583\u20137. https:\/\/doi.org\/10.1016\/j.amjmed.2016.12.006.","journal-title":"Am J Med"},{"issue":"4","key":"2416_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/09546630152696314","volume":"12","author":"A Akar","year":"2001","unstructured":"Akar A, Bulent Tastan H, Erbil H, Arca E, Kurumlu Z, Gur AR. Efficacy and safety assessment of 0.5% and 1% colchicine cream in the treatment of actinic keratoses. J Dermatolog Treat. 2001;12(4):199\u2013203. https:\/\/doi.org\/10.1080\/09546630152696314.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"2416_CR17","first-page":"515","volume":"19","author":"I Akdag","year":"2006","unstructured":"Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K. Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure. J Nephrol. 2006;19(4):515\u20137.","journal-title":"J Nephrol"},{"issue":"7-8","key":"2416_CR18","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1345\/aph.1E593","volume":"39","author":"G Alayli","year":"2005","unstructured":"Alayli G, Cengiz K, Canturk F, Durmus D, Akyol Y, Menekse EB. Acute myopathy in a patient with concomitant use of pravastatin and colchicine. Ann Pharmacother. 2005;39(7-8):1358\u201361. https:\/\/doi.org\/10.1345\/aph.1E593.","journal-title":"Ann Pharmacother"},{"issue":"4 Suppl 26","key":"2416_CR19","first-page":"S13","volume":"20","author":"MR Altiparmak","year":"2002","unstructured":"Altiparmak MR, Pamuk ON, Pamuk GE, Hamuryudan V, Ataman R, Serdengecti K. Colchicine neuromyopathy: a report of six cases. Clin Exp Rheumatol. 2002;20(4 Suppl 26):S13\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"2416_CR20","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s10067-007-0682-2","volume":"26","author":"A Altman","year":"2007","unstructured":"Altman A, Szyper-Kravitz M, Shoenfeld Y. Colchicine-induced rhabdomyolysis. Clin Rheumatol. 2007;26(12):2197\u20139. https:\/\/doi.org\/10.1007\/s10067-007-0682-2.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"2416_CR21","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/mus.20135","volume":"30","author":"SK Baker","year":"2004","unstructured":"Baker SK, Goodwin S, Sur M, Tarnopolsky MA. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve. 2004;30(6):799\u2013802. https:\/\/doi.org\/10.1002\/mus.20135.","journal-title":"Muscle Nerve"},{"issue":"4","key":"2416_CR22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/s0736-4679(02)00430-4","volume":"22","author":"RA Bonnel","year":"2002","unstructured":"Bonnel RA, Villalba ML, Karwoski CB, Beitz J. Deaths associated with inappropriate intravenous colchicine administration. J Emerg Med. 2002;22(4):385\u20137. https:\/\/doi.org\/10.1016\/s0736-4679(02)00430-4.","journal-title":"J Emerg Med"},{"issue":"5","key":"2416_CR23","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1345\/aph.1A288","volume":"36","author":"KH Boomershine","year":"2002","unstructured":"Boomershine KH. Colchicine-induced rhabdomyolysis. Ann Pharmacother. 2002;36(5):824\u20136. https:\/\/doi.org\/10.1345\/aph.1A288.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"2416_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/RHU.0b013e3182056042","volume":"17","author":"R Bouquie","year":"2011","unstructured":"Bouquie R, Deslandes G, Renaud C, Dailly E, Haloun A, Jolliet P. Colchicine-induced rhabdomyolysis in a heart\/lung transplant patient with concurrent use of cyclosporin, pravastatin, and azithromycin. J Clin Rheumatol. 2011;17(1):28\u201330. https:\/\/doi.org\/10.1097\/RHU.0b013e3182056042.","journal-title":"J Clin Rheumatol"},{"issue":"8","key":"2416_CR25","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1097\/01.SMJ.0000163315.02563.B2","volume":"98","author":"VC Cheng","year":"2005","unstructured":"Cheng VC, Ho PL, Yuen KY. Two probable cases of serious drug interaction between clarithromycin and colchicine. South Med J. 2005;98(8):811\u20133. https:\/\/doi.org\/10.1097\/01.SMJ.0000163315.02563.B2.","journal-title":"South Med J"},{"issue":"2","key":"2416_CR26","first-page":"204","volume":"5","author":"SS Choi","year":"1999","unstructured":"Choi SS, Chan KF, Ng HK, Mak WP. Colchicine-induced myopathy and neuropathy. Hong Kong Med J. 1999;5(2):204\u20137.","journal-title":"Hong Kong Med J"},{"issue":"2","key":"2416_CR27","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1345\/aph.10184","volume":"35","author":"AJ Dixon","year":"2001","unstructured":"Dixon AJ, Wall GC. Probable colchicine-induced neutropenia not related to intentional overdose. Ann Pharmacother. 2001;35(2):192\u20135. https:\/\/doi.org\/10.1345\/aph.10184.","journal-title":"Ann Pharmacother"},{"issue":"9","key":"2416_CR28","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/15563650701779703","volume":"46","author":"G Eleftheriou","year":"2008","unstructured":"Eleftheriou G, Bacis G, Fiocchi R, Sebastiano R. Colchicine-induced toxicity in a heart transplant patient with chronic renal failure. Clin Toxicol (Phila). 2008;46(9):827\u201330. https:\/\/doi.org\/10.1080\/15563650701779703.","journal-title":"Clin Toxicol (Phila)"},{"issue":"9","key":"2416_CR29","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1016\/j.transproceed.2012.09.028","volume":"44","author":"C Garrouste","year":"2012","unstructured":"Garrouste C, Philipponnet C, Kaysi S, Enache I, Tiple A, Heng AE. Severe colchicine intoxication in a renal transplant recipient on cyclosporine. Transplant Proc. 2012;44(9):2851\u20132. https:\/\/doi.org\/10.1016\/j.transproceed.2012.09.028.","journal-title":"Transplant Proc"},{"issue":"5","key":"2416_CR30","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/00002826-200209000-00008","volume":"25","author":"WC Hsu","year":"2002","unstructured":"Hsu WC, Chen WH, Chang MT, Chiu HC. Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin. Clin Neuropharmacol. 2002;25(5):266\u20138. https:\/\/doi.org\/10.1097\/00002826-200209000-00008.","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"2416_CR31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.krcp.2013.04.003","volume":"32","author":"K Huh","year":"2013","unstructured":"Huh K, Joung JY, Jeong H, Je D, Cho YY, Jang HR, et al. Colchicine-induced myoneuropathy in a cyclosporine-treated renal transplant recipient. Kidney Res Clin Pract. 2013;32(2):74\u20137. https:\/\/doi.org\/10.1016\/j.krcp.2013.04.003.","journal-title":"Kidney Res Clin Pract"},{"issue":"5","key":"2416_CR32","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/RHU.0b013e318156d977","volume":"13","author":"M Justiniano","year":"2007","unstructured":"Justiniano M, Dold S, Espinoza LR. Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine. J Clin Rheumatol. 2007;13(5):266\u20138. https:\/\/doi.org\/10.1097\/RHU.0b013e318156d977.","journal-title":"J Clin Rheumatol"},{"issue":"10","key":"2416_CR33","doi-asserted-by":"publisher","first-page":"498","DOI":"10.5694\/j.1326-5377.2000.tb124076.x","volume":"172","author":"PA Kubler","year":"2000","unstructured":"Kubler PA. Fatal colchicine toxicity. Med J Aust. 2000;172(10):498\u20139.","journal-title":"Med J Aust"},{"issue":"25","key":"2416_CR34","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1056\/NEJM198706183162502","volume":"316","author":"RW Kuncl","year":"1987","unstructured":"Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M. Colchicine myopathy and neuropathy. N Engl J Med. 1987;316(25):1562\u20138. https:\/\/doi.org\/10.1056\/NEJM198706183162502.","journal-title":"N Engl J Med"},{"issue":"2","key":"2416_CR35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1440-1797.2006.00542.x","volume":"11","author":"IC Lai","year":"2006","unstructured":"Lai IC, Cheng CY, Chen HH, Chen WY, Chen PY. Colchicine myoneuropathy in chronic renal failure patients with gout. Nephrology (Carlton). 2006;11(2):147\u201350. https:\/\/doi.org\/10.1111\/j.1440-1797.2006.00542.x.","journal-title":"Nephrology (Carlton)"},{"issue":"2","key":"2416_CR36","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3346\/jkms.1997.12.2.160","volume":"12","author":"BI Lee","year":"1997","unstructured":"Lee BI, Shin SJ, Yoon SN, Choi YJ, Yang CW, Bang BK. Acute myopathy induced by colchicine in a cyclosporine-treated renal transplant recipient--a case report and review of the literature. J Korean Med Sci. 1997;12(2):160\u20131. https:\/\/doi.org\/10.3346\/jkms.1997.12.2.160.","journal-title":"J Korean Med Sci"},{"issue":"1265","key":"2416_CR37","first-page":"U2808","volume":"120","author":"J Ly","year":"2007","unstructured":"Ly J, Gow P, Dalbeth N. Colchicine prescribing and safety monitoring in patients with gout. N Z Med J. 2007;120(1265):U2808.","journal-title":"N Z Med J"},{"issue":"10","key":"2416_CR38","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.pmrj.2016.03.003","volume":"8","author":"C Marciniak","year":"2016","unstructured":"Marciniak C, Babu A, Ghannad L, Burnstine R, Keeshin S. Unusual electromyographic findings associated with colchicine neuromyopathy: a case report. PM R. 2016;8(10):1016\u20139. https:\/\/doi.org\/10.1016\/j.pmrj.2016.03.003.","journal-title":"PM R"},{"issue":"2","key":"2416_CR39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.5414\/CN108343","volume":"86","author":"S Medani","year":"2016","unstructured":"Medani S, Wall C. Colchicine toxicity in renal patients - are we paying attention? Clin Nephrol. 2016;86(2):100\u20135. https:\/\/doi.org\/10.5414\/CN108343.","journal-title":"Clin Nephrol"},{"issue":"10","key":"2416_CR40","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1093\/oxfordjournals.ndt.a027096","volume":"11","author":"JJ Montseny","year":"1996","unstructured":"Montseny JJ, Meyrier A, Gherardi RK. Colchicine toxicity in patients with chronic renal failure. Nephrol Dial Transplant. 1996;11(10):2055\u20138. https:\/\/doi.org\/10.1093\/oxfordjournals.ndt.a027096.","journal-title":"Nephrol Dial Transplant"},{"issue":"7426","key":"2416_CR41","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1136\/bmj.327.7426.1275","volume":"327","author":"I Morris","year":"2003","unstructured":"Morris I, Varughese G, Mattingly P. Colchicine in acute gout. BMJ. 2003;327(7426):1275\u20136. https:\/\/doi.org\/10.1136\/bmj.327.7426.1275.","journal-title":"BMJ."},{"issue":"7","key":"2416_CR42","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3109\/15563650.2011.589844","volume":"49","author":"M Mullins","year":"2011","unstructured":"Mullins M, Cannarozzi AA, Bailey TC, Ranganathan P. Unrecognized fatalities related to colchicine in hospitalized patients. Clin Toxicol (Phila). 2011;49(7):648\u201352. https:\/\/doi.org\/10.3109\/15563650.2011.589844.","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"2416_CR43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/jama.247.1.58","volume":"247","author":"DJ Nashel","year":"1982","unstructured":"Nashel DJ, Chandra M. Acute gouty arthritis. Special management considerations in alcoholic patients. JAMA. 1982;247(1):58\u20139. https:\/\/doi.org\/10.1001\/jama.247.1.58.","journal-title":"JAMA."},{"issue":"3","key":"2416_CR44","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/art.1780290324","volume":"29","author":"MN Neuss","year":"1986","unstructured":"Neuss MN, McCallum RM, Brenckman WD, Silberman HR. Long-term colchicine administration leading to colchicine toxicity and death. Arthritis Rheum. 1986;29(3):448\u20139. https:\/\/doi.org\/10.1002\/art.1780290324.","journal-title":"Arthritis Rheum"},{"issue":"24","key":"2416_CR45","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJM197406132902406","volume":"290","author":"RW Ortel","year":"1974","unstructured":"Ortel RW, Newcombe DS. Acute gouty arthritis and response to colchicine in the virtual absence of synovial-fluid leukocytes. N Engl J Med. 1974;290(24):1363\u20134. https:\/\/doi.org\/10.1056\/NEJM197406132902406.","journal-title":"N Engl J Med"},{"key":"2416_CR46","doi-asserted-by":"publisher","first-page":"3191089","DOI":"10.1155\/2016\/3191089","volume":"2016","author":"S Patel","year":"2016","unstructured":"Patel S, Andres J, Qureshi K. An unexpected interaction between sofosbuvir\/ledipasvir and atorvastatin and colchicine causing rhabdomyolysis in a patient with impaired renal function. Case Rep Med. 2016;2016:3191089. https:\/\/doi.org\/10.1155\/2016\/3191089.","journal-title":"Case Rep Med"},{"issue":"7","key":"2416_CR47","first-page":"1566","volume":"34","author":"D Petersel","year":"2007","unstructured":"Petersel D, Schlesinger N. Treatment of acute gout in hospitalized patients. J Rheumatol. 2007;34(7):1566\u20138.","journal-title":"J Rheumatol"},{"issue":"4","key":"2416_CR48","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/s0303-8467(97)00092-9","volume":"99","author":"SS Rana","year":"1997","unstructured":"Rana SS, Giuliani MJ, Oddis CV, Lacomis D. Acute onset of colchicine myoneuropathy in cardiac transplant recipients: case studies of three patients. Clin Neurol Neurosurg. 1997;99(4):266\u201370. https:\/\/doi.org\/10.1016\/s0303-8467(97)00092-9.","journal-title":"Clin Neurol Neurosurg"},{"issue":"6","key":"2416_CR49","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1097\/00007890-199006000-00041","volume":"49","author":"EH Rieger","year":"1990","unstructured":"Rieger EH, Halasz NA, Wahlstrom HE. Colchicine neuromyopathy after renal transplantation. Transplantation. 1990;49(6):1196\u20138.","journal-title":"Transplantation."},{"issue":"7","key":"2416_CR50","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/(SICI)1097-4598(199607)19:7<870::AID-MUS9>3.0.CO;2-6","volume":"19","author":"SB Rutkove","year":"1996","unstructured":"Rutkove SB, De Girolami U, Preston DC, Freeman R, Nardin RA, Gouras GK, et al. Myotonia in colchicine myoneuropathy. Muscle Nerve. 1996;19(7):870\u20135. https:\/\/doi.org\/10.1002\/(SICI)1097-4598(199607)19:7<870::AID-MUS9>3.0.CO;2-6.","journal-title":"Muscle Nerve"},{"issue":"1","key":"2416_CR51","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s40800-015-0020-6","volume":"2","author":"YC Su","year":"2015","unstructured":"Su YC, Wu CC. Colchicine-induced acute neuromyopathy in a patient using concomitant fluconazole: case report and literature review. Drug Saf Case Rep. 2015;2(1):16. https:\/\/doi.org\/10.1007\/s40800-015-0020-6.","journal-title":"Drug Saf Case Rep"},{"issue":"5","key":"2416_CR52","first-page":"204","volume":"66","author":"W van der Velden","year":"2008","unstructured":"van der Velden W, Huussen J, Ter Laak H, de Sevaux R. Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin. Neth J Med. 2008;66(5):204\u20136.","journal-title":"Neth J Med"},{"issue":"12","key":"2416_CR53","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1592\/phco.24.17.1784.52334","volume":"24","author":"K Wilbur","year":"2004","unstructured":"Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and literature review. Pharmacotherapy. 2004;24(12):1784\u201392. https:\/\/doi.org\/10.1592\/phco.24.17.1784.52334.","journal-title":"Pharmacotherapy."},{"issue":"10","key":"2416_CR54","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3899\/jrheum.170387","volume":"44","author":"S Wright","year":"2017","unstructured":"Wright S, Chapman PT, Frampton C, O'Donnell JL, Raja R, Stamp LK. Management of gout in a hospital setting: a lost opportunity. J Rheumatol. 2017;44(10):1493\u20138. https:\/\/doi.org\/10.3899\/jrheum.170387.","journal-title":"J Rheumatol"},{"issue":"5","key":"2416_CR55","first-page":"1199","volume":"28","author":"KH Yoon","year":"2001","unstructured":"Yoon KH. Colchicine induced toxicity and pancytopenia at usual doses and treatment with granulocyte colony-stimulating factor. J Rheumatol. 2001;28(5):1199\u2013200.","journal-title":"J Rheumatol"},{"issue":"2","key":"2416_CR56","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/14397595.2017.1318467","volume":"28","author":"J Yu","year":"2018","unstructured":"Yu J, Qiu Q, Liang L, Yang X, Xu H. Prophylaxis of acute flares when initiating febuxostat for chronic gouty arthritis in a real-world clinical setting. Mod Rheumatol. 2018;28(2):339\u201344. https:\/\/doi.org\/10.1080\/14397595.2017.1318467.","journal-title":"Mod Rheumatol"},{"key":"2416_CR57","doi-asserted-by":"publisher","first-page":"6602","DOI":"10.1186\/1757-1626-2-6602","volume":"2","author":"B Zagler","year":"2009","unstructured":"Zagler B, Kaneppele A, Pattis P, Stockner I, Sitzmann G, Widmann J, et al. Patient risk factors and adverse drug interactions in the treatment of acute gouty arthritis in the elderly: a case report. Cases J. 2009;2:6602. https:\/\/doi.org\/10.1186\/1757-1626-2-6602.","journal-title":"Cases J"},{"issue":"2","key":"2416_CR58","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/ar3297","volume":"13","author":"N Schlesinger","year":"2011","unstructured":"Schlesinger N, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther. 2011;13(2):R53. https:\/\/doi.org\/10.1186\/ar3297.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"2416_CR59","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","volume":"71","author":"N Schlesinger","year":"2012","unstructured":"Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839\u201348. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200908.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2416_CR60","doi-asserted-by":"publisher","first-page":"R28","DOI":"10.1186\/ar2143","volume":"9","author":"A So","year":"2007","unstructured":"So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28. https:\/\/doi.org\/10.1186\/ar2143.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"2416_CR61","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1002\/art.27600","volume":"62","author":"A So","year":"2010","unstructured":"So A, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010;62(10):3064\u201376. https:\/\/doi.org\/10.1002\/art.27600.","journal-title":"Arthritis Rheum"},{"key":"2416_CR62","unstructured":"Sunkureddi P, Bardin T, Alten RE, Schlesinger N, Bloch M, Kiechle T, et al. Effect of IL-1 inhibition with canakinumab compared to triamcinolone acetonide on pain intensity and new flares in gouty arthritis patients with chronic kidney disease stage 2\u20135. Arthritis Rheum. 2011;63."},{"key":"2416_CR63","first-page":"447","volume":"2013","author":"P Sunkureddi","year":"2013","unstructured":"Sunkureddi P, Bardin T, Alten RE, Schlesinger N, Bloch M, Kiechle T, et al. Efficacy and safety of canakinumab in gouty arthritis patients with chronic kidney disease stage \u22653. Ann Rheum Dis. 2013;2013:447.","journal-title":"Ann Rheum Dis"},{"key":"2416_CR64","first-page":"1083","volume":"73","author":"P Sunkureddi","year":"2014","unstructured":"Sunkureddi P, Toth E, Brown J, Kivitz A, Stancati A, Richard D, et al. Efficacy and safety of canakinumab pre-filled syringe in acute gouty arthritis patients with chronic kidney disease stage \u22653. Arthritis Rheum. 2014;73:1083.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"2416_CR65","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/ard.2009.108936","volume":"68","author":"R Terkeltaub","year":"2009","unstructured":"Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis. 2009;68(10):1613\u20137. https:\/\/doi.org\/10.1136\/ard.2009.108936.","journal-title":"Ann Rheum Dis"},{"key":"2416_CR66","unstructured":"Terkeltaub R, Evans RR, Weinstein SP, Wu R, Schumacher HR. Rilonacept for gout flare prophylaxis in patients with chronic kidney disease: analysis of 3 clinical trials. Arthritis Rheum. 2012;64."},{"issue":"12","key":"2416_CR67","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1093\/rheumatology\/kex325","volume":"56","author":"S Adler","year":"2017","unstructured":"Adler S, Seitz M. The gouty spine: old guy-new tricks. Rheumatology (Oxford). 2017;56(12):2243\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/kex325.","journal-title":"Rheumatology (Oxford)"},{"key":"2416_CR68","doi-asserted-by":"publisher","first-page":"792173","DOI":"10.1155\/2015\/792173","volume":"2015","author":"A Aouba","year":"2015","unstructured":"Aouba A, Deshayes S, Frenzel L, Decottignies A, Pressiat C, Bienvenu B, et al. Efficacy of anakinra for various types of crystal-induced arthritis in complex hospitalized patients: a case series and review of the literature. Mediat Inflamm. 2015;2015:792173. https:\/\/doi.org\/10.1155\/2015\/792173.","journal-title":"Mediat Inflamm"},{"issue":"8","key":"2416_CR69","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/RHU.0000000000000047","volume":"19","author":"JB Bartov","year":"2013","unstructured":"Bartov JB, Ali Y. Successful use of the interleukin 1 antagonist, anakinra, in a patient with gout, chronic kidney disease, and aplastic anemia. J Clin Rheumatol. 2013;19(8):454\u20136. https:\/\/doi.org\/10.1097\/RHU.0000000000000047.","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"2416_CR70","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.semarthrit.2010.03.001","volume":"40","author":"K Chen","year":"2010","unstructured":"Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L. Anakinra\u2019s efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum. 2010;40(3):210\u20134. https:\/\/doi.org\/10.1016\/j.semarthrit.2010.03.001.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"2416_CR71","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jbspin.2012.04.009","volume":"79","author":"G Direz","year":"2012","unstructured":"Direz G, Noel N, Guyot C, Toupance O, Salmon JH, Eschard JP. Efficacy but side effects of anakinra therapy for chronic refractory gout in a renal transplant recipient with preterminal chronic renal failure. Joint Bone Spine. 2012;79(6):631. https:\/\/doi.org\/10.1016\/j.jbspin.2012.04.009.","journal-title":"Joint Bone Spine"},{"issue":"3","key":"2416_CR72","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3899\/jrheum.130688","volume":"41","author":"S Donmez","year":"2014","unstructured":"Donmez S, Pamuk ON. Chronic tophaceous gout. J Rheumatol. 2014;41(3):554\u20135. https:\/\/doi.org\/10.3899\/jrheum.130688.","journal-title":"J Rheumatol"},{"issue":"3","key":"2416_CR73","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/rheumatology\/keq358","volume":"50","author":"T Funck-Brentano","year":"2011","unstructured":"Funck-Brentano T, Salliot C, Leboime A, Zafrani L, Servais A, Larousserie F, et al. First observation of the efficacy of IL-1ra to treat tophaceous gout of the lumbar spine. Rheumatology (Oxford). 2011;50(3):622\u20134. https:\/\/doi.org\/10.1093\/rheumatology\/keq358.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"2416_CR74","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/acr.21989","volume":"65","author":"P Ghosh","year":"2013","unstructured":"Ghosh P, Cho M, Rawat G, Simkin PA, Gardner GC. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res. 2013;65(8):1381\u20134. https:\/\/doi.org\/10.1002\/acr.21989.","journal-title":"Arthritis Care Res"},{"issue":"9","key":"2416_CR75","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1002\/art.24694","volume":"61","author":"SB Gratton","year":"2009","unstructured":"Gratton SB, Scalapino KJ, Fye KH. Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis Rheum. 2009;61(9):1268\u201370. https:\/\/doi.org\/10.1002\/art.24694.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2416_CR76","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.jbspin.2018.03.015","volume":"85","author":"C Loustau","year":"2018","unstructured":"Loustau C, Rosine N, Forien M, Ottaviani S, Juge PA, Liote F, et al. Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: a multicentre, retrospective study. Joint Bone Spine. 2018;85(6):755\u201360. https:\/\/doi.org\/10.1016\/j.jbspin.2018.03.015.","journal-title":"Joint Bone Spine"},{"issue":"1","key":"2416_CR77","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40744-018-0104-8","volume":"5","author":"D Marotto","year":"2018","unstructured":"Marotto D, De Santis A, Chessa D, Firinu D, Del Giacco S. A Beacon in the dark: canakinumab. A new therapeutic perspective in chronic tophaceous gout. Rheumatol Ther. 2018;5(1):303\u201310. https:\/\/doi.org\/10.1007\/s40744-018-0104-8.","journal-title":"Rheumatol Ther"},{"issue":"12","key":"2416_CR78","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1136\/ard.2007.073759","volume":"66","author":"D McGonagle","year":"2007","unstructured":"McGonagle D, Tan AL, Shankaranarayana S, Madden J, Emery P, McDermott MF. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis. 2007;66(12):1683\u20134. https:\/\/doi.org\/10.1136\/ard.2007.073759.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2416_CR79","doi-asserted-by":"publisher","first-page":"R123","DOI":"10.1186\/ar4303","volume":"15","author":"S Ottaviani","year":"2013","unstructured":"Ottaviani S, Molto A, Ea HK, Neveu S, Gill G, Brunier L, et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther. 2013;15(5):R123. https:\/\/doi.org\/10.1186\/ar4303.","journal-title":"Arthritis Res Ther"},{"key":"2416_CR80","unstructured":"Palma C, Topping T, Tabechian D. Anakinra is effective and well tolerated in medically complex patients including transplant recipients with gout. Arthritis Rheum. 2016."},{"key":"2416_CR81","doi-asserted-by":"publisher","first-page":"A707","DOI":"10.1136\/annrheumdis-2011-201164","volume":"72","author":"F Perez-Ruiz","year":"2013","unstructured":"Perez-Ruiz F, Herrero-Beites AM, Alonso-Ruiz A, Atxotegi J, Lopez-Santamaria MR, de Miguel M. Low-dose anakinra is effective for the prophylaxis of acute episodes of inflammation in severe tophaceous gout. Ann Rheum Dis. 2013;72:A707.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2416_CR82","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/RHU.0b013e3181be2423","volume":"15","author":"D Singh","year":"2009","unstructured":"Singh D, Huston KK. IL-1 inhibition with anakinra in a patient with refractory gout. J Clin Rheumatol. 2009;15(7):366. https:\/\/doi.org\/10.1097\/RHU.0b013e3181be2423.","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"2416_CR83","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1111\/j.1756-185X.2011.01629.x","volume":"14","author":"AP Tran","year":"2011","unstructured":"Tran AP, Edelman J. Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout. Int J Rheum Dis. 2011;14(3):e33\u20137. https:\/\/doi.org\/10.1111\/j.1756-185X.2011.01629.x.","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"2416_CR84","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/s0002-9343(89)80153-6","volume":"87","author":"LE Kahl","year":"1989","unstructured":"Kahl LE, Thompson ME, Griffith BP. Gout in the heart transplant recipient: physiologic puzzle and therapeutic challenge. Am J Med. 1989;87(3):289\u201394. https:\/\/doi.org\/10.1016\/s0002-9343(89)80153-6.","journal-title":"Am J Med"},{"key":"2416_CR85","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1136\/annrheumdis-2012-eular.1657","volume":"71","author":"E Mikhnevich","year":"2013","unstructured":"Mikhnevich E, Lemiasheuskaya S. Factors associated with refractoriness to NSAIDS in GOUTY arthritis. Ann Rheum Dis. 2013;71:444.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2416_CR86","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/ki.1993.293","volume":"44","author":"D Schlondorff","year":"1993","unstructured":"Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int. 1993;44(3):643\u201353. https:\/\/doi.org\/10.1038\/ki.1993.293.","journal-title":"Kidney Int"},{"issue":"3","key":"2416_CR87","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/rheumatology\/keh043","volume":"43","author":"S Bajaj","year":"2004","unstructured":"Bajaj S, Fessler BJ, Alarcon GS. Systemic lupus erythematosus and gouty arthritis: an uncommon association. Rheumatology (Oxford). 2004;43(3):349\u201352. https:\/\/doi.org\/10.1093\/rheumatology\/keh043.","journal-title":"Rheumatology (Oxford)"},{"key":"2416_CR88","doi-asserted-by":"publisher","first-page":"657694","DOI":"10.1155\/2012\/657694","volume":"2012","author":"S Fargetti","year":"2012","unstructured":"Fargetti S, Goldenstein-Schainberg C, Silva Abreu A, Fuller R. Refractory gout attack. Case Rep Med. 2012;2012:657694. https:\/\/doi.org\/10.1155\/2012\/657694.","journal-title":"Case Rep Med"},{"issue":"6","key":"2416_CR89","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/00124743-199912000-00007","volume":"5","author":"R Hausch","year":"1999","unstructured":"Hausch R, Wilkerson M, Singh E, Reyes C, Harrington T. Tophaceous gout of the thoracic spine presenting as back pain and fever. J Clin Rheumatol. 1999;5(6):335\u201341. https:\/\/doi.org\/10.1097\/00124743-199912000-00007.","journal-title":"J Clin Rheumatol"},{"issue":"11","key":"2416_CR90","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1756-185X.2008.00380.x","volume":"2008","author":"CL Hill","year":"2008","unstructured":"Hill CL, Lu TY, Cervelli M, Mathew T. Failure of rasburicase therapy in recurrent acute gout with tophi. Int J Rheum Dis. 2008;2008(11):315\u20137.","journal-title":"Int J Rheum Dis"},{"issue":"12","key":"2416_CR91","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00296-009-0882-y","volume":"29","author":"H Karimzadeh","year":"2009","unstructured":"Karimzadeh H, Mohtasham N, Karimifar M, Salesi M, Bonakdar ZS. A case of ochronosis with gout and Monckeberg arteries. Rheumatol Int. 2009;29(12):1507\u201310. https:\/\/doi.org\/10.1007\/s00296-009-0882-y.","journal-title":"Rheumatol Int"},{"issue":"6","key":"2416_CR92","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2169\/internalmedicine.53.0698","volume":"53","author":"M Maekawa","year":"2014","unstructured":"Maekawa M, Tomida H, Aoki T, Hishida M, Morinaga T, Tamai H. Successful treatment of refractory gout using combined therapy consisting of febuxostat and allopurinol in a patient with chronic renal failure. Intern Med. 2014;53(6):609\u201312. https:\/\/doi.org\/10.2169\/internalmedicine.53.0698.","journal-title":"Intern Med"},{"issue":"6","key":"2416_CR93","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/ncprheum0214","volume":"2","author":"P Richette","year":"2006","unstructured":"Richette P, Bardin T. Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. Nat Clin Pract Rheumatol. 2006;2(6):338\u201342; quiz 43. https:\/\/doi.org\/10.1038\/ncprheum0214.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2416_CR94","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1590\/S0482-50042009000600011","volume":"49","author":"JF Sarmento","year":"2009","unstructured":"Sarmento JF, Cavalcante VDA, M.T.R. S, Braz ADS, Freire EAM. Chronic tophaceous gout mimicking rheumatoid arthritis. Rev Bras Reumatol. 2009;49:741\u20136.","journal-title":"Rev Bras Reumatol"},{"key":"2416_CR95","doi-asserted-by":"publisher","first-page":"397646","DOI":"10.1155\/2011\/397646","volume":"2011","author":"AK Tausche","year":"2011","unstructured":"Tausche AK, Wunderlich C, Aringer M. Tophaceous gout and renal insufficiency: a new solution for an old therapeutic dilemma. Case Rep Med. 2011;2011:397646. https:\/\/doi.org\/10.1155\/2011\/397646.","journal-title":"Case Rep Med"},{"issue":"6","key":"2416_CR96","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3941\/jrcr.v4i6.332","volume":"4","author":"D Udayakumar","year":"2010","unstructured":"Udayakumar D, Kteleh T, Alfata S, Bali T, Joseph A. Spinal gout mimicking paraspinal abscess: a case report. J Radiol Case Rep. 2010;4(6):15\u201320. https:\/\/doi.org\/10.3941\/jrcr.v4i6.332.","journal-title":"J Radiol Case Rep"},{"issue":"4","key":"2416_CR97","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.27327","volume":"62","author":"RA Terkeltaub","year":"2010","unstructured":"Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060\u20138. https:\/\/doi.org\/10.1002\/art.27327.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2416_CR98","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.semarthrit.2019.11.002","volume":"50","author":"S Stewart","year":"2020","unstructured":"Stewart S, Tallon A, Taylor WJ, Gaffo A, Dalbeth N. How flare prevention outcomes are reported in gout studies: a systematic review and content analysis of randomized controlled trials. Semin Arthritis Rheum. 2020;50(2):303\u201313. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.11.002.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"2416_CR99","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/art.40381","volume":"70","author":"AL Gaffo","year":"2018","unstructured":"Gaffo AL, Dalbeth N, Saag KG, Singh JA, Rahn EJ, Mudano AS, et al. Brief report: validation of a definition of flare in patients with established gout. Arthritis Rheum. 2018;70(3):462\u20137. https:\/\/doi.org\/10.1002\/art.40381.","journal-title":"Arthritis Rheum"},{"key":"2416_CR100","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cct.2018.03.015","volume":"68","author":"S Timilsina","year":"2018","unstructured":"Timilsina S, Brittan K, O'Dell JR, Brophy M, Davis-Karim A, Henrie AM, et al. Design and rationale for the veterans affairs \u201ccooperative study program 594 comparative effectiveness in gout: allopurinol vs. febuxostat\u201d trial. Contemp Clin Trials. 2018;68:102\u20138. https:\/\/doi.org\/10.1016\/j.cct.2018.03.015.","journal-title":"Contemp Clin Trials"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02416-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02416-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02416-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T07:12:00Z","timestamp":1619593920000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02416-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2416"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02416-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"assertion":[{"value":"18 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N\/A.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declared no conflict of interests. G-Can is supported at arm\u2019s length unrestricted by grants from pharma companies in last 12\u2009months that was horizon and Astra Zeneca and LG.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}